Company
Celgene
30 published works
Rivkin Rounds
Cigna Sues Bristol Myers Squibb Alleging Scheme to Block Generic Drug
Cigna filed a lawsuit on June 24 in Manhattan federal court accusing Bristol Myers Squibb of unlawfully blocking generic versions of its blood cancer drug, Pomalyst, from entering the market.…
New York Commercial Division Practice
Stop Blaming the Parents! – The Scope of Parental Liability for a Subsidiary’s Contract
Misbehaving children? Blame the parents, right? Not so in the corporate context, at least according to Manhattan Commercial Division Justice Robert R. Reed in a recent decision, Memorial Sloan Kettering…
Intellectual Property Law Blog
Amgen Inc. v. Sandoz Inc, No. 2022-1147 (Fed. Cir. Apr. 19, 2023)
By Zijian Han, Sheppard Mullin
This case is an appellate review of the district court’s findings regarding patent obviousness and priority date. Background Amgen produces and markets apremilast, a medication for the treatment of certain…
Allens Insights
InIP: ACCC delivers bitter pill on patent settlement
By Allens
ACCC proposes to deny authorisation for patent settlement 5 min read The ACCC proposes to deny authorisation for a patent litigation settlement between Celgene and two generic drug companies. The…
Harness Dickey Blog
Patent Venue Construed Strictly, Even in ANDA Litigation
By Todd
In Celgene Corp. v. Mylan Pharmaceutics Inc., [2021-1154] (November 5, 2021) the Federal Circuit affirmed the dismissal of a patent infringement action against defendants, MPI and Mylan Inc., for improper…
Drug & Device Law
D. Minnesota Dumps Non-Diverse Plaintiff’s Claim for Lack of Personal Jurisdiction
Today’s case, BCBSM, Inc. v. Celgene Corp., 2021U.S. Dist. LEXIS 52785 (March 22, 2021), is an antitrust case. The plaintiffs alleged that a pharma company suppressed generic competition. We enjoy…
Life Sciences Legal Insights
Biotech & Life Sciences Trends to Consider Following JPM 2020: M&A, Venture Capital and More
The annual gathering of life sciences executives and investors in San Francisco that many now call “JPM Week” recently concluded, marking the J.P. Morgan Healthcare Conference’s 38th year. The Big…
The CLS Blue Sky Blog
Wachtell Lipton Discusses Mergers and Acquisitions—2020
Despite ebbs and flows of global economic uncertainty, M&A activity remained robust in 2019. Total deal volume reached $4 trillion globally, a slight decrease from the $4.1 trillion volume in…
Adams on Contract Drafting
Dual Verb Structures: “Shall Grant and Hereby Grants”
By Ken Adams
In this post a couple of weeks ago, I belatedly introduced the topic of dual verb structures. Here’s another dual verb structure: shall grant/assign and hereby grants/assigns (and variants). It…
Life Sciences Securities Litigation
District Court Judge Partially Dismisses Claims Against Celgene, But Allows Allegations Regarding Misleading Statements About Sales Projections and FDA Approval to Proceed
By Gregg Weiner, Adam Harris, Life Sciences Litigation & Enforcement Team
In re Celgene Corp. Sec. Litig., 2019 WL 6909463 (D.N.J. Dec. 19, 2019) On December 19, 2019, Judge John Michael Vazquez of the District of New Jersey partially denied a…